An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders

 With your risk of dementia post stroke your competent? doctor needs to run this so appropriate dementia prevention protocols can be initiated. Your competent? doctor has those EXACT PROTOCOLS, right? Oh no, you DON'T have a functioning stroke doctor, do you?

The reason you need dementia prevention: 

1. A documented 33% dementia chance post-stroke from an Australian study?   May 2012.

2. Then this study came out and seems to have a range from 17-66%. December 2013.

3. A 20% chance in this research.   July 2013. 

 I bet your doctor has failed to create EXACT dementia prevention protocols, and s/he is still employed by your hospital?

An FDG-PET-Based Machine Learning Framework to Support Neurologic Decision-Making in Alzheimer Disease and Related Disorders  

Leland Barnard  ¹ , Hugo Botha  ¹ , Nick Corriveau-Lecavalier  ² , Jonathan Graff-Radford  ¹ , Ellen Dicks  ¹ , Venkatsampath Gogineni  ¹ , Gemeng Zhang  ¹ , Brian J Burkett  ³ , Derek R Johnson  ³ , Sean J Huls  ³ , Aditya Khurana  ³ , John L Stricker  ⁴ , Hoon-Ki Paul Min  ³ , Matthew L Senjem  ⁴ , Winnie Z Fan  ⁵ , Heather Wiste  ⁶ , Mary M Machulda  ² , Melissa E Murray  ⁷ , Dennis W Dickson  ⁷ , Aivi T Nguyen  ⁸ , R Ross Reichard  ⁸ , Jeffrey L Gunter  ³ , Christopher G Schwarz  ³ , Kejal Kantarci  ³ , Jennifer L Whitwell  ³ , Keith Anthony Josephs  ¹ , David S Knopman  ¹ , Bradley F Boeve  ¹ , Ronald C Petersen  ¹ , Clifford R Jack  ³ , Val J Lowe  ³ , David T Jones  ^{1   3} ; Alzheimer's Disease Neuroimaging Initiative

Affiliations

• PMID: 40577677
• PMCID: PMC12207676 (available on 2026-07-22)
• DOI: 10.1212/WNL.0000000000213831

Abstract

Background and objectives: Distinguishing neurodegenerative diseases is a challenging task requiring neurologic expertise. Clinical decision support systems (CDSSs) powered by machine learning (ML) and artificial intelligence can assist with complex diagnostic tasks by augmenting user capabilities, but workflow integration poses many challenges. We propose that a modeling framework based on fluorodeoxyglucose PET (FDG-PET) imaging can address these challenges and form the basis of an effective CDSS for neurodegenerative disease.

Methods: This retrospective study focused on FDG-PET images in a discovery cohort drawn from 3 research studies plus routine clinical patients. When selecting research study participants, the inclusion criterion was the availability of an FDG-PET image from within 2.5 years of diagnosis with 1 of 9 specific neurodegenerative syndromes or designation as unimpaired. Participants from disease groups were recruited from the clinical patient population while unimpaired participants came primarily from a population study. The discovery cohort was used to develop a clinical decision support framework we call StateViewer, which applies a neighbor matching algorithm to detect the presence of 9 different neurodegenerative phenotypes. The ML performance of this framework was evaluated in the discovery cohort by nested cross-validation and externally validated in the Alzheimer's Disease Neuroimaging Initiative. Potential for clinical integration was demonstrated in a radiologic reader study focused on differentiating posterior cortical atrophy from Lewy body dementia.

Results: The discovery cohort contained 3,671 individuals with a mean age of 68 years and consisted of 49% reported female. Our model framework was able to detect the presence of 9 different neurodegenerative phenotypes with a sensitivity of 0.89 ± 0.03 and an area under the receiver operating characteristic curve of 0.93 ± 0.02. In the radiologic reader study, readers using our model were found to have 3.3 ± 1.1 times greater odds of making a correct diagnosis than readers using a current standard-of-care workflow.

Discussion: Our proposed framework provides strong classification performance with high interpretability, and it addresses many of the challenges that face clinical integration of ML-based decision support tools. One limitation of this study is a uniform discovery cohort that is not representative of other patient populations in some regards.